Cutera, Inc (CUTR) Q2 2024 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call reveals several challenges: declining revenue, inventory management issues, gross margin decline, and significant cash burn. Despite some positive aspects like AviClear's international growth, the Q&A highlights concerns about sales force turnover, macro pressures, and vague guidance on cash burn. These factors, combined with no share buyback and the need for additional capital, suggest a negative sentiment, likely leading to a stock price decline in the range of -2% to -8% over the next two weeks.

Key Financial Performance

Total Revenue $34.4 million, a decrease of $27.4 million or 44% year-over-year, primarily due to a $13.8 million decline in North American capital equipment revenue, a $9.4 million decline in skin care revenue, and a $3 million decline in consumables revenue.

Non-GAAP Gross Profit $9.6 million, with a gross margin rate of 28.8%, down from 46.6% year-over-year, driven by decreased sales volume and a change in sales mix, including a shift from North America to Europe.

Non-GAAP Operating Expenses $30.9 million, a decrease of $11.2 million year-over-year, mainly due to personnel savings from restructuring and lower sales commissions.

Non-GAAP Loss from Operations $21.3 million, compared to a loss of $13.2 million in the prior year period.

Cash and Cash Equivalents $84.3 million, down from $105.4 million at the end of Q1 2024, a decrease of $21.1 million primarily due to a $16.7 million net cash loss for the quarter and inventory purchase commitments.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

AviClear Systems: International launch of AviClear is proceeding exceedingly well with over 70 systems sold outside of North America.

xeo+ Launch: Highly positive feedback from the launch of xeo+ in North America, exceeding expectations with more sales into new accounts.

Partnership with L'Oreal: New partnership with L'Oreal's SkinCeuticals business in Japan, expected to launch in Q4 2024.

Sales Force Restructuring: Strengthened North American sales force with new leadership and a focus on improved productivity.

Cost Reductions: Identified additional cost savings expected to annualize at approximately $10 million in 2025.

Operational Excellence: Continued progress in product reliability, field service, inventory control, and cost of operations.

Market Positioning: Transitioning from lease model for systems, with expectations of returning over half of the original lease installed base.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Macroeconomic Pressure: The company is experiencing continued macroeconomic pressure, which is affecting capital purchase activity and customer access to financing, limiting their ability to invest in new capital.

Sales Force Transition: The transition of the sales force has led to a decline in revenue, particularly in North America, impacting overall performance.

Inventory Management: The company is facing challenges with inventory management, including a significant amount of inventory that needs to be worked down, which is affecting cash flow.

Gross Margin Decline: Gross margin was below expectations due to lower sales volume and a shift in sales mix, particularly a decline in higher-margin RF energy platforms.

Cash Burn and Working Capital: The company anticipates a cash outflow of over $25 million related to working capital in 2024, with a delayed realization of inventory work-down benefits.

Regulatory and Market Risks: The company faces risks related to regulatory approvals and market dynamics, particularly in the context of launching new products and expanding into new geographies.

Debt and Capital Structure: There is a need to evaluate liquidity and capital structure options, including reducing debt and potentially bringing in additional capital to fund growth initiatives.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

New Commercial Leadership: Cutera has appointed Steve Kreider as SVP of North America to lead a unified commercial organization, focusing on capital sales, practice development, marketing, and customer excellence.

Cost Reductions: Identified additional cost savings expected to annualize at approximately $10 million in 2025, following a previous restructuring that reduced headcount by 25% and expenses by $20 million.

AviClear Launch: The international launch of AviClear is progressing well, with over 70 systems sold outside North America and positive utilization rates.

Partnership with L'Oreal: Cutera has partnered with L'Oreal's SkinCeuticals in Japan, planning to launch in Q4 2024.

Revenue Guidance: Revised full year revenue guidance to a range of $140 million to $145 million, down from $160 million to $170 million.

Cash Balance Guidance: Expected cash, cash equivalents, and restricted cash balance at December 31, 2024, revised to approximately $40 million, down from $55 million to $60 million.

Cash Burn Improvement: Anticipate a year-over-year improvement in cash burn of over $50 million from 2024 to 2025, primarily due to working capital adjustments.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

Share Buyback Program: None

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:Any additional color on additional markets that are coming in coming quarters for AviClear?

A:We've really had almost flawless launch of AviClear internationally. It's proceeding at or above the levels that we had anticipated. In the second quarter, we were up in terms of revenue versus the first quarter of the launch. We expect the launch to continue to trend in that upward direction, but some markets like Japan may not launch this year.

Q:Do you think the SkinCeuticals line has the potential to approach 20% of total company sales?

A:We have all the building blocks in place to make this a very important product line for Cutera. We do think that there's a ton of potential over time, but I wouldn't expect that over the next 2 years we will approach the peak levels we got to with the xeo skin health line.

Q:Can you outline the impact from the sales force turnover versus the macro environment on the reduction in revenue guidance?

A:The vast majority of the reduction is in North America, with both macro pressures and sales force turnover affecting us. It's hard to parse those out, but they could have been almost equal contributors. We had approximately 40% turnover in the North America capital organization during the second quarter.

Q:Is there any sort of cadence we should expect in the back half for cash burn guidance?

A:The back half of the year will have lower burn than the first half, but not as low as previously thought due to the shift in timing of working capital benefit. The fourth quarter is expected to have a higher level of burn than we should have entering 2025.

Q:Are you seeing macro weakness in the med spas, and is that spreading across other end markets?

A:This is more concentrated in the med spa community, primarily due to access to capital issues. It's tougher for a segment of customers to get financing, but we're not seeing it as a major issue in the medical community.

Q:Can you provide more color on AviClear's growth expectations in North America?

A:AviClear is a clear growth driver for us internationally, and we're transitioning to an ownership model in North America focused on the most productive users. We're seeing great feedback and believe we are set up well to grow the AviClear franchise.

Q:Review of Unclear Management Responses

A:Management's response regarding the potential of the SkinCeuticals line lacked specific quantification and clarity on how quickly it could approach previous sales levels. Additionally, the discussion on the cash burn guidance was somewhat vague, particularly regarding the specifics of the timing and impact of working capital changes.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

CUTR Transcript

Cutera, Inc. (CUTR) Q3 2024 Earnings Call Transcript

Unknown11-10

The earnings call reflects several negative factors: a significant revenue decline, reduced guidance, high bad debt expenses, and inventory management challenges. Despite some cost reductions and a new partnership with L'Oreal, competitive pressures and regulatory uncertainties persist. The Q&A session highlighted management's evasiveness on certain topics and ongoing challenges in the North American market. These factors, combined with no shareholder return plan, suggest a negative sentiment. However, the potential for future growth in international markets and improved cash burn provide some balance, resulting in a 'Negative' prediction for stock price movement.

Cutera, Inc (CUTR) Q2 2024 Earnings Call Transcript

Unknown8-10

Cutera, Inc. (CUTR) Q1 2024 Earnings Call Transcript

Neutral5-10

Cutera, Inc. (CUTR) Q4 2023 Earnings Call Transcript

Unknown3-22

The earnings call reveals significant challenges: a 26% revenue drop, plummeting gross margins, and a substantial operating loss. The Q&A highlights uncertainties in revenue guidance, cash burn, and the AviClear business model. Management's vague responses further exacerbate concerns. Despite a planned product launch, the transition to in-house manufacturing, and efforts to revitalize AviClear, the negative financial performance and lack of clear guidance suggest a likely negative stock price reaction.

CUTR Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.